LAUSR

This study compared HbA1c control, treatment patterns, and costs in adults with T2DM initiated on CANA or a GLP-1 based on administrative claims data from the HealthCore Integrated Research Database (4/2013-02/2016) augmented with laboratory data. The analysis included adult patients with ≥1 HbA1c result at baseline (BL) and in the 12-month follow-up period; statistical analysis was performed at 3-month intervals. Inverse probability of treatment weighting (IPTW) accounted for differences in BL characteristics. From 12 months pre- to 12 months post-index (Figure), there were no significant differences in HbA1c at each 3-month interval in patients initiated on CANA (n = 750) or GLP-1 (n = 2417); results were consistent regardless of BL HbA1c (≥7%, ≥8%, or ≥9%) (data not shown). A greater proportion of patients were adherent to index medication (proportion of days covered ≥80%) over 12 months with CANA vs. GLP-1 (47.5% vs. 37.5%; P In summary, CANA initiation resulted in similar HbA1c values, greater adherence, less discontinuation, and lower treatment cost compared to GLP-1 in T2DM patients. Disclosure M. Singhal: Other Relationship; Self; Janssen Scientific Affairs, LLC. H. Tan: Other Relationship; Self; Janssen Scientific Affairs, LLC. C.I. Coleman: Research Support; Self; Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc. W.H. Herman: Other Relationship; Self; Merck Sharp & Dohme Corp., Lexicon Pharmaceuticals, Inc.. Consultant; Self; Janssen Scientific Affairs, LLC.. Research Support; Spouse/Partner; Nestle. Other Relationship; Self; American Diabetes Association. Advisory Panel; Self; National Committee for Quality Assurance (NCQA). J. Cai: Employee; Self; Janssen Scientific Affairs, LLC. M. Han: Employee; Self; Janssen Scientific Affairs, LLC. M. Ingham: Employee; Self; Janssen Scientific Affairs, LLC..